N E Kay|P D Markham - JoVE Visualize

Showing results (151-160 of 183) with videos related to

Pageof 19

Sort By:

International Journal of Cancer|November 15, 1988

Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6)D V Ablashi, P Lusso, C L Hung, et al.

JAMA|October 18, 1985

HTLV-III infection among health care workers. Association with needle-stick injuriesS H Weiss, W C Saxinger, D Rechtman, et al.

JAMA|March 15, 1985

Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDSR R Redfield, P D Markham, S Z Salahuddin, et al.

British Journal of Haematology|June 10, 2000

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patientsR Fonseca, M C Trendle, T Leong, et al.

Blood|October 1, 1996

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III TrialP Liu, T Leong, L Quam, et al.

Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1991

Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primatesA Hosmalin, P L Nara, M Zweig, et al.

AIDS (London, England)|January 11, 2000

Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaquesL J Patterson, B Peng, A G Abimiku, et al.

Lancet (London, England)|March 15, 1986

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complexR Yarchoan, R W Klecker, K J Weinhold, et al.

Leukemia & Lymphoma|February 1, 1996

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myelomaM M Oken, R A Kyle, P R Greipp, et al.

Cancer|September 24, 1999

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486M M Oken, T Leong, R E Lenhard, et al.

Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:

Pageof 19

International Journal of Cancer|November 15, 1988

Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6)D V Ablashi, P Lusso, C L Hung, et al.

JAMA|October 18, 1985

HTLV-III infection among health care workers. Association with needle-stick injuriesS H Weiss, W C Saxinger, D Rechtman, et al.

JAMA|March 15, 1985

Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDSR R Redfield, P D Markham, S Z Salahuddin, et al.

British Journal of Haematology|June 10, 2000

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patientsR Fonseca, M C Trendle, T Leong, et al.

Blood|October 1, 1996

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III TrialP Liu, T Leong, L Quam, et al.

Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1991

Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primatesA Hosmalin, P L Nara, M Zweig, et al.

AIDS (London, England)|January 11, 2000

Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaquesL J Patterson, B Peng, A G Abimiku, et al.

Lancet (London, England)|March 15, 1986

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complexR Yarchoan, R W Klecker, K J Weinhold, et al.

Leukemia & Lymphoma|February 1, 1996

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myelomaM M Oken, R A Kyle, P R Greipp, et al.

Cancer|September 24, 1999

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486M M Oken, T Leong, R E Lenhard, et al.

Pageof 19